Key Takeaways from Bristol-Myers Squibb's Earnings

Bristol-Myers Squibb (NYSE: BMY  ) reported mixed earnings for first quarter 2014 -- revenue declined by about 1% to $3.8 billion, as a decline in U.S. revenue of 10% was almost offset by a 10% lift in international revenue. Gross margin increased slightly to 75% from 72% last year, and marketing, selling, and administration expense declined to $960 million, helping drive an increase in adjusted EPS to $0.46.

That top line decline was due in part to Bristol's divestment of its half of a diabetes partnership with AstraZeneca  (NYSE: AZN  ) (Bristol sold it to Astra for $4.3 billion). Individual drug performance was good, with Baraclude up 11% and the oncology franchise helping drive growth as well.

There were several other important takeaways from the quarter which helped generate additional revenue growth -- in the video below, Motley Fool health care analysts Michael Douglass and David Williamson discuss the quarter and what to watch for moving forward.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2941958, ~/Articles/ArticleHandler.aspx, 8/28/2015 11:22:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated Moments ago Sponsored by:
DOW 16,616.10 -38.67 -0.23%
S&P 500 1,987.13 -0.53 -0.03%
NASD 4,815.37 2.66 0.06%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 11:07 AM
BMY $60.75 Down -0.07 -0.12%
Bristol-Myers Squi… CAPS Rating: ****
AZN $31.50 Down -0.11 -0.35%
AstraZeneca plc (A… CAPS Rating: ****